47 unknown, 19 completed, 13 recruiting, 5 not yet recruiting. 38 Phase 2, 36 Phase 1, 11 Phase 3, 9 Phase 4.
Follow Betta Pharmaceuticals Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug-Drug Interaction Study of Vorolanib Tablets in Healthy Participants vorolanib and rifampicin, vorolanib and itraconazole - DDI (Drug-Drug Interaction) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer Icotinib, Routine Observational - NSCLC (Non-small Cell Lung Cancer) | Recruiting | Betta Pharmaceuticals Co., Ltd. | 2572 | 2026-09-01 | 2026-09-08 | |
| Pharmacokinetic Study of Vorolanib Tablets in Trial Participants With Hepatic Impairment vorolanib, Vorolanib - Hepatic Impairment (HI) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| Drug-Drug Interaction Study of Befotertinib Capsules in Healthy Participants. Befotertinib and rifampicin, Befotertinib and itraconazole - DDI (Drug-Drug Interaction) | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 36 | 2026-09-01 | 2026-09-09 |
| Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC Combined group of ensatinib and arotinib - ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib | Phase 4 | Not yet recruiting | Qiming Wang | 80 | 2026-07-01 | 2026-06-26 |
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. MCLA-129, Ensartinib - Solid Advanced Tumor | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 164 | 2026-01-31 | 2026-03-04 |
| Study of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS BPI-572270 - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 120 | 2026-01-29 | 2026-09-18 |
| Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI Befotertinib, Pemetrexed + Carboplatin - NSCLC, Adjuvant Drug Therapy | Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 28 | 2025-09-01 | 2025-09-30 |
| Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification. MCLA-129 - Non-Small Cell Lung Cancer | Phase 2 | Not yet recruiting | Betta Pharmaceuticals Co., Ltd. | 100 | 2025-03-31 | 2025-03-20 |
| Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD Ensartinib - NSCLC, Stage I, II, IIIA, IIIB | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 70 | 2025-01-15 | 2025-01-17 |
| A Phase I Study of CFT8919 in Patients With Advanced NSCLC Dose-Escalation (Phase Ia) CFT8919 capsule, Dose-Expansion (Phase Ib) CFT8919 capsule, Cohort-Expansion (Phase Ic) CFT8919 capsule - Non-Small Cell Lung Cancer With EGFR Mutation | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 166 | 2024-11-04 | 2026-09-04 |
| A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers Ensartinib, Rifampicin, Itraconazole - Healthy | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 36 | 2024-07-01 | 2024-07-09 |
| Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD - Non-Small Cell Lung CancerãEGFR Sensitive Mutation | Phase 1 | Not yet recruiting | Betta Pharmaceuticals Co., Ltd. | 172 | 2023-09-01 | 2023-08-29 |
| BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors BPB-101 - Solid Tumor | Phase 1 / Phase 2 | Unknown | Betta Pharmaceuticals Co., Ltd. | 388 | 2023-05-16 | 2023-06-06 |
| A Study of BPI-452080 in Subjects With Solid Tumors BPI-452080 - Solid Tumor, Renal Cell Carcinoma | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 87 | 2023-04-28 | 2023-05-06 |
| A Study of BPI-460372 in Advanced Solid Tumor Patients BPI-460372 - Advanced Solid Tumor | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 82 | 2023-04-24 | 2025-01-27 |
| Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo - Non-Small Cell Lung Cancer, EGFR Sensitive Mutation | Phase 3 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 570 | 2023-03-28 | 2023-09-22 |
| A Phase 1 Study of BPI-371153 in Subjects with Advanced Solid Tumors or Relapsed/Refractory Lymphoma BPI-371153 - Advanced Solid Tumor, Lymphoma | Phase 1 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 110 | 2022-08-29 | 2025-01-27 |
| Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients BPI-442096 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Unknown | Betta Pharmaceuticals Co., Ltd. | 230 | 2022-06-01 | 2022-06-21 |
| A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer BPI-16350, placebo, Fulvestrant - Breast Cancer | Phase 3 | Unknown | Betta Pharmaceuticals Co., Ltd. | 274 | 2022-05-25 | 2023-07-27 |
Showing 20 of 89. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (42) · Brain Neoplasms (6) · Adenocarcinoma (5) · Colorectal Neoplasms (4) · Pancreatic Neoplasms (4) · Neoplasm Metastasis (3) · Psoriasis (3) · Lung Neoplasms (2) · Breast Neoplasms (1) · Carcinoma, Renal Cell (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Nasopharyngeal Carcinoma (1)
icotinib (36) · ensartinib (13) · Drug Therapy (7) · Pemetrexed (6) · Gemcitabine (3) · Itraconazole (3) · Rifampin (3) · Docetaxel (2) · Vinorelbine (2) · vorolanib (2) · Arsenic Trioxide (1) · BPI-3016 (1) · Bevacizumab (1) · Capsules (1) · Carboplatin (1)
China (84) · Australia (1) · New Zealand (1)
Yuankai Shi, MD (3) · Li Zhang, MD (2) · Shugeng Gao (2) · Shun Lu, M.D. (2) · Xiaohua Hu, MD (2) · Yan Sun, MD (2) · Zhang Yi Ping, M.D. (2) · Bai Chunmei, MD (1) · Binghe Xu, Ph.D (1) · Caicun Zhou, MD (1) · Caicun Zhou, Ph.D (1) · Chen Ming (1) · Christopher J Wynne (1) · Dingwei Ye, Ph.D (1) · DongYing Liu (1)
PMID 23948351, PMID 22112293, PMID 26599904, PMID 26980473, PMID 28945850, PMID 31628085, PMID 31948451, PMID 32606956, PMID 33044566, PMID 34280355, PMID 34841235, PMID 35724798, PMID 35862035, PMID 36647478, PMID 37041472, PMID 37244266, PMID 37348348, PMID 39256512, PMID 40403388, PMID 40421698, PMID 40742733, PMID 42418775, PMID 42660909, PMID 42855739